Setback for Lilly eye drug

Share this article:
The FDA late last week asked Eli Lilly to submit more data about its experimental diabetic retinopathy drug Arxxant before it can be approved for sale. The two-page letter Lilly received from the FDA doesn’t make clear whether Lilly will have to conduct an entirely new patient trial or if the company can satisfy the agency’s request for more information by re-analyzing data already in hand, a Lilly spokeswoman told The Indianapolis Star newspaper. If Lilly has to conduct a new clinical trial, it is likely that the marketing of Arxxant would be set back by several years. The FDA had agreed to do an expedited six-month review of the Arxxant application, given Lilly’s urgency to get a treatment on the market. If approved, Arxxant would have been the first drug on the market to treat diabetic retinopathy, a deterioration of vision that commonly afflicts people with diabetes. Analysts have predicted Arxxant could become a $1 billion-a-year blockbuster by 2010.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.